ACRV – acrivon therapeutics, inc. (US:NASDAQ)

News

Acrivon Therapeutics gets FDA breakthrough device designation for its oncosignature assay for endometrial cancer [Seeking Alpha]
Acrivon Therapeutics Announces FDA has Granted Breakthrough Device Designation for ACR-368 OncoSignature Assay for Endometrial Cancer
Acrivon Therapeutics, Inc. (NASDAQ: ACRV) is now covered by analysts at Cantor Fitzgerald. They set an "overweight" rating on the stock.
Acrivon Therapeutics, Inc. (NASDAQ: ACRV) is now covered by analysts at KeyCorp. They set an "overweight" rating on the stock.
Show more
Live Event: Join our next subscriber-only event: "The Data Driven Investor"
Register for our next upcoming LIVE training session, which will be hosted on Tuesday April 24th at 08:00 PM EST (New York Time).
Get your questions answered during the Q & A session.
For any support questions, contact our team: support@newsquantified.com